No description available.

No description available.

<p> The striatum is a key brain region involved in regulating motor output and integration. The dorsal and ventral subdivisions of the striatum work in concert to mediate the reinforcing and motor behavioral outputs of the striatum. Moreover, dysfunction of these striatal regions is involved in various diseases including Parkinson’s disease and drug addiction. Therefore, understanding and characterizing biochemical and molecular changes within the striatum associated with these diseases is key in devolving novel therapeutics to treat these disease states. The main output neurons of the striatum are GABAergic, medium-spiny neurons (MSNs), and striatal functionality is mediated by neuroplastic changes in MSN activity. Within MSNs, dopaminergic receptor activation triggers a cascade of reversable phosphorylation, which is facilitated by the activation of specific protein kinases and inhibition of specific protein phosphatases. In comparison to the 350 serine/threonine protein kinases expressed within the striatum, there are only 40 major serine/threonine protein phosphatases. However, serine/threonine protein phosphatases, such as protein phosphatase 1 (PP1), gain their target specificity by interacting with phosphatase-targeting proteins. Within the striatum, the neurabins, termed neurabin and spinophilin, are the most abundant PP1 targeting proteins in dendritic spines. Spinophilin’s expression in the striatum has been strongly characterized, and spinophilin has been shown to regulate striatal-dependent motor-skill learning and amphetamine-induced locomotor sensitization. In contrast to spinophilin, neurabin’s expression within the striatum and its involvement in these striatal-dependent behaviors has not been fully probed. I found that neurabin expression in the striatum is not sex-dependent but is age-dependent. In addition to these data, I also present validation of new global, constitutive and conditional neurabin knock-out mouse lines. Finally, I present data that, unlike previous studies in spinophilin knockout mice, neurabin knockout mice have enhanced striatal-dependent motor-skill learning, but do not impact amphetamine-induced locomotor sensitization. Further characterization of neurabin’s expression in the striatum, and its role in these key striatal behaviors could provide a druggable target for therapeutics designed to address striatal dysfunction.   </p>

The tachykinin NK-3 receptor is a G-protein coupled receptor activated by mammalian tachykinin neuropeptides, which can modulate dopaminergic neurotransmission, and alter dopamine-mediated behaviors. The NK-3 receptor is currently under investigation as a novel therapeutic target for cocaine addiction. Our studies, as outlined in this dissertation, sought to determine if NK-3 receptors have a functional role in the acute as well as long-term behavioral effects of cocaine. Administration of NK-3 receptor agonists or antagonists potentiates or attenuates dopamine-mediated behaviors, respectively. Based on these findings, we hypothesized that blockade of neurokinin-3 receptors would alter acute and long-term behavioral responses to cocaine. We investigated whether acute and repeated administration of the NK-3 receptor antagonist SB 222200 altered hyperactivity induced by cocaine, and determined a possible mechanism involving dopamine D1 receptors in the striatum. We also determined whether NK-3 receptor blockade altered the development and expression of behavioral sensitization after repeated cocaine administration. Lastly, we investigated whether modulation of behavioral effects of acute and repeated cocaine by NK-3 receptors involved GSK3 phosphorylation in the nucleus accumbens. As described in this dissertation, we show that acute administration of the NK-3 receptor antagonist SB 222200 before a cocaine injection attenuated stereotypic responses produced by cocaine. Repeated administration of SB 222200 enhanced stereotypic activity produced by either cocaine or a low dose of SKF 82958 (0.125 mg/kg, i.p.) when administered seven days later. Dopamine receptor binding studies were performed to determine the mechanism of enhanced stereotypic responses. Binding studies showed a 19.7% increase in dopamine D1 receptor density in the striatum seven days later after repeated SB 222200 administration. These findings demonstrate that acute blockade of NK-3 receptors attenuated cocaine-induced behaviors in agreement with previous studies. Furthermore, these studies also show novel effects of repeated blockade of NK-3 receptors, which causes subsequent enhancement of cocaine and dopamine D1 receptor-mediated behaviors, possibly resulting from dopamine D1 receptor up-regulation in the striatum. In order to determine a role of NK-3 receptors in the development of cocaine-induced behavioral sensitization, the NK-3 receptor antagonist SB 222200 (2.5 or 5 mg/kg, s.c.) was administered prior to daily cocaine injections for 5 days. After a 7-day drug-free period, behavioral responses to a cocaine challenge were measured. Repeated administration of cocaine for 5 days induced a sensitized response upon a cocaine challenge 7 days later. Administration of SB 222200 prior to daily cocaine attenuated the development of behavioral sensitization. Moreover, administration of SB 222200 prior to the cocaine challenge blocked the expression of behavioral sensitization. These findings demonstrate that NK-3 receptor activity is involved in the development and expression of behavioral sensitization to cocaine. Lastly, we examined GSK3 phosphorylation in the nucleus accumbens induced by acute and repeated cocaine administration and determined if phosphorylation was altered by NK-3 receptor blockade. Similar to the drug administration regimens used in the behavioral studies, the NK-3 receptor antagonist SB 222200 was administered 30 mins prior to an acute cocaine injection. The nucleus accumbens was examined for changes in GSK3 phosphorylation by Western blot analysis. Increases in phosphorylation of the isoforms, GSK3α and GSK3β in the nucleus accumbens were detected 20 mins after an acute injection of cocaine. NK-3 receptor blockade prior to cocaine administration did not alter the cocaine-induced increase in GSK3 phosphorylation. Similar to the behavioral sensitization studies, SB 222200 was administered prior to repeated cocaine for 5 days, and 7 days later GSK3 phosphorylation was measured after a subsequent cocaine challenge. In contrast to the increases in GSK3α and GSK3β in the nucleus accumbens after an acute cocaine injection, no regulation of GSK3 phosphorylation was found after prior repeated cocaine administration and cocaine challenge. Administration of SB 222200 prior to repeated cocaine produced an increase in GSK3α and GSK3β phosphorylation after a cocaine challenge. Collectively, these data point to involvement of NK-3 receptor activity in changes in the phosphorylation of GSK3 in the nucleus accumbens produced by cocaine. In summary, functional involvement of NK-3 receptors in acute and long-term behavioral effects of cocaine was investigated. In agreement with previous findings, studies in this dissertation demonstrate that acute blockade of NK-3 receptors attenuates cocaine-induced behaviors. In addition, we found novel effects of repeated blockade of NK-3 receptors on cocaine-induced hyperactivity. There is enhancement of subsequent cocaine and dopamine D1 receptor-mediated behaviors possibly due to dopamine D1 receptor up-regulation in the striatum. NK-3 receptor activity was shown to be involved in long-term behavioral effects of cocaine and molecular changes in GSK3 phosphorylation in the nucleus accumbens. Blockade of NK-3 receptors prevented the development and expression of behavioral sensitization to cocaine and also blocked the changes in the phosphorylation of GSK3 in the nucleus accumbens. This dissertation has demonstrated a role of NK-3 receptors in modulating acute as well long-term cocaine-induced behavioral hyperactivity. Therefore, there is potential clinical relevance of NK-3 receptors in cocaine abuse and dependence as a therapeutic target for treatment, which warrants further characterization in future preclinical and clinical investigations. / Pharmacology

As virtual experiences are rapidly substituting a significant proportion of in-person interactions during the COVID pandemic, it is critical to monitor the effect of screen exposure time on developing children’s behavior and nervous system. Screen use boosts information accessibility and, therefore, may delay the development of the inhibitory control networks in children, who are vulnerable to immediate reward-orientated tendencies and not yet capable of controlling their impulsivity. Therefore, it was hypothesized that as children become more exposed to screens, the development of the inhibitory control network would be delayed and their reward sensitivity will be augmented. Using the ABCD Study Data Repository, 8,334 children’s behavioral and neural data (aged 9-11) were included. Robust mediation analysis and correlation analysis were used to investigate how Screen Time interacts with children’s reward-orientated tendency (e.g. Behavioral approach system, BAS) and the brain's inhibitory network. Intrinsic Frontoparietal Network-Striatum (FPN-Striatum) connectivity strength was used as neural indices of the inhibitory control quality in children. Results showed that Screen Time significantly mediated the relationship between BAS and both waves of the intrinsic inhibitory process. A higher BAS was linked to a longer Screen Time and weaker inhibitory network connectivity. This complete/full mediation model indicates that Screen Time negatively influenced the strength of FPN-Striatum connectivity. In conclusion, the study revealed specific behavioral and neural correlates of screen exposure using a large database, and suggested that increasing screen exposure time may impair the inhibitory capability and increase impulsivity in children. / M.S. / The current study explored the effect of daily screen exposure in pre-adolescent children to provide an important springboard for future work in protecting developing children against the negative impacts of screen use, which has increased significantly during the COVID-19 pandemic. Over 8,000 children’s data from the Adolescent Brain Cognitive Development (ABCD) project was included and found that an increased daily screen exposure time is linked to an inefficient inhibitory control system in the brain. As children’s inhibitory control systems are still developing, this negative effect further hinder the maturation of inhibitory-control systems two years later. Given that the virtual movement is irreversible, the results provide scientific evidence that a balance between screen time and non-screen activities is required for developing children.

Depression and other mood disorders, as well as cognitive and motor dysfunction have been linked with changes in monoamine levels in the brain. Environmental acetylcholinesterase (AChE) inhibitors, such as organophosphate insecticides (OPs), have also been shown to induce these problems. This study investigated whether insecticide-induced AChE inhibition, induced by chlorpyrifos (CPS), may contribute to the types of forebrain monoaminergic alterations associated with psychiatric, cognitive and motor dysfunction. Increased synaptic ACh, resulting from CPS-induced AChE inhibition, may alter the synthesis or release of monoamines through prolonged action of ACh on monoaminergic neurons that contain ACh receptors. Adult, male Sprague-Dawley rats were subjected to a single subcutaneous dose of CPS or corn oil vehicle. Brains were rapidly removed and the frontal cortex, hippocampus and striatum were bilaterally dissected on ice. These three regions from one side were assayed for AChE activity, while those from the opposite side were processed for high performance liquid chromatography with electrochemical detection (HPLC-ED) analysis of monoamine neurotransmitters and their metabolites. In the initial, exploratory experiment, inhibition of AChE activity was 66.8% in the frontal cortex, 43.8% in the hippocampus and 46.9% in the striatum, 7 days after a 60mg/kg dose of CPS. No significant differences in concentration of monoamine neurochemicals were observed between vehicle control and CPS-treated groups in either the hippocampus or striatum. However, in the frontal cortex of the CPS-treated rats there was a significant increase in median dihydroxyphenylacetic acid (DOPAC) concentration (P=0.019) and a very strong statistical trend toward increased dopamine (DA) concentration (P=0.0506). The second experiment examined the time course of AChE inhibition produced by a higher dose (200mg/kg) of CPS and how monoamine levels changed in conjunction with this pattern of AChE inhibition. Percent inhibition of AChE activity in CPS-treated animals, at 4, 14 and 21 days post-exposure was 77.0%, 86.6% and 81.9% in the frontal cortex, 86.1%, 85.9% and 83.2% in the hippocampus and 90.1%, 89.8% and 85.5% in the striatum. No significant differences in monoamine neurochemicals were observed between vehicle control and CPS-treated groups in either the hippocampus or striatum. A statistical trend toward a decrease in serotonin (5-HT) was seen in the frontal cortex at 14 days (P=0.0753) following CPS exposure. A very consistent, yet non-significant pattern of an increase in monoamines at 4 days post-CPS was observed in all instances, except for 5-hydroxyindoleacetic acid (5-HIAA) in the striatum. Therefore, the final experiment employed a more powerful design to focus on monoamine levels during, or shortly after, the change in AChE activity that rapidly follows exposure to 200mg/kg CPS. This experiment also employed a behavioral analysis on the day of sacrifice to assess the presence or absence of clinical signs of toxicity associated with this dose. Of the 30 CPS-treated rats, only 1 animal displayed a single behavioral sign of cholinergic poisoning. Percent inhibition of AChE activity at 2 and 4 days after treatment was 81.4% and 79.4% in the frontal cortex, 53.4% and 83.5% in the hippocampus, and 80.5% and 87.8% in the striatum. No significant changes in monoamine neurochemicals were observed between vehicle control and CPS-treated groups in either the frontal cortex or hippocampus. However, a significant increase in DOPAC (P=0.0285) in the striatum, 2 days after CPS treatment, was observed. In addition, a strong statistical trend toward decreased striatal 5-HT (P=0.0645) was reported 4 days after CPS treatment. The only significant correlation between AChE activity and monoamine concentration was observed for 5-HIAA in the striatum of CPS-treated, 2 day survivors (P=0.0445). However, it was of low magnitude (r=0.525, r2=0.276). CPS has a limited capacity to produce changes in monoamine neurotransmitters and/or their metabolites in the frontal cortex and striatum of the mammalian brain. These changes are primarily seen in the dopaminergic system. Alterations of monoamines do not appear to be strongly associated with incident levels of AChE inhibition. The biological implication of the limited OP induced changes in central monoamines remains significant, as changes in monoamines in the CNS nervous system have been linked to psychiatric, cognitive and motor dysfunction. / Master of Science

Einleitung: Bei der Dystonie handelt es sich um eine Erkrankung des zentralen Nervensystems. Sie ist charakterisiert durch ungewollte, dauerhafte oder wiederkehrende Muskelkontraktionen, die zu abnormalen Bewegungsabläufen und Haltungen führen. Sie ist die dritthäufigste Bewe-gungsstörung beim Menschen. Bisherige Befunde beim Menschen und Untersuchungen an Tier-modellen weisen u.a. auf eine besondere Bedeutung der Basalganglien-Thalamus-Schleife hin, die an der Kontrolle von willkürlichen und unwillkürlichen Bewegungen beteiligt ist. So konnten bei unterschiedlichen Tiermodellen Veränderungen im Striatum (STR), der Eingangsstruktur der Basalganglien, nachgewiesen werden. Beim dtsz Hamster, einem gut etablierten Tiermodell für die paroxysmale Dystonie, konnte neben vielen striatalen Veränderungen eine Reduktion der GABAergen Interneurone (IN), wie Parvalbumin-positive (PV+) IN, zum Zeitpunkt der maximalen Ausprägung der Dystonie gezeigt werden. Ziele der Untersuchung: Die Gründe für den Mangel an striatalen GABAergen IN bei der dtsz Hamstermutante sollten weiter untersucht werden, indem der Frage nachzugehen war, ob beim dtsz Hamster eine Migrations- oder Ausreifungsstörung der IN vorliegt. Dazu wurde das Homöodomänprotein Nkx 2.1, als Marker für aus dem medialen Ganglienhügel eingewanderte IN, im STR der dtsz Hamstermutante untersucht. Die Expression des Brain-derived neurotrophic factors (BDNF), des Kalium-Chlorid-Kotransporters 2 (KCC2) und die zytosolische Carboanhydrase vom Isotyp 7 (CAH7) wurden als Indikatoren für die Ausreifung von GABAergen IN herangezogen. Tiere, Material und Methoden: Die Untersuchungen wurden vergleichend an dtsz Hamstern und Kontrollhamstern durchgeführt. Beim dtsz Hamster zeigt die Dystonie einen altersabhängigen Verlauf (Beginn: ca. 16. Lebenstag (LT); Maximum: 30.-42. LT; Remission: 70. LT). Deshalb wurden als Untersuchungszeitpunkte der 18. LT und der 33. LT gewählt. Um die Migration der striatalen IN zu untersuchen, wurde im STR bei 33 Tage alten Hamsterns die Dichte der immun-histochemisch markierten Nkx 2.1-positiven Zellen stereologisch ermittelt. Der mRNA-Gehalt wurde relativ mittels „quantitativer Echtzeit-PCR“ (qPCR) bestimmt. Zusätzlich wurde die mRNA-Expression von Nkx 2.1 bei 18 Tage alten Tieren untersucht. Von KCC2 und CAH7 wurde die mRNA mittels qPCR bei 18 und 33 Tage alten Hamstern im STR untersucht. Die Expression von BDNF wurde mittels ELISA-System im Kortex (Cx), STR und im restlichen Gehirngewebe („R“) bei 33 und 18 Tage alten Tieren bestimmt. Der BDNF-mRNA Gehalt wurde im Cx (18. und 33. LT) und im STR (33. LT) untersucht. Des Weiteren sollte BDNF bei 33 Tage alten Hamstern mittels immunhistochemischer Markierung im Cx und STR untersucht werden. Die Untersuchung von BDNF im Cx ist deshalb wichtig, weil BDNF vom Cx in das STR trans-portiert wird. Zusätzlich wurde Parvalbumin (PV) zusammen mit Nkx 2.1 immunhistochemisch markiert und die mRNA-Expression von PV bei 18 und 33 Tage alten Tieren bestimmt. Ergebnisse: Für Nkx 2.1 konnte kein Unterschied in der Zelldichte zwischen dtsz- und Kontroll-hamstern gefunden werden. Ebenfalls gab es weder bei 18 noch bei 33 Tage alten Tieren einen Unterschied in der Nkx 2.1-mRNA-Expression. Unterschiede in der mRNA-Expression von KCC2 und CAH7 im STR (18. und 33. LT) lagen auch nicht vor. Die Expression der PV-mRNA im STR bei 33 Tage alten Tieren war jedoch erwartungsgemäß vermindert. Auf mRNA-Ebene konnte im Cx für BDNF kein Unterschied zwischen dtsz- und Kontrolltiergruppe gefunden wer-den. Bei beiden Tiergruppen wurde mittels ELISA im STR mehr BDNF nachgewiesen als im Cx und im R (18. und 33. LT) nachweisbar. Entgegen der Hypothese war nach Analyse der Daten mittels Zwei-Wege ANOVA eine geringe Erhöhung der BDNF-Expression im Cx und STR bei 33 Tage alten dtsz Hamstern nachweisbar. Dies lag daran, dass die BDNF-Expression nur bei den Kontrolltieren am 33. LT im Vergleich zum 18. LT herunterreguliert war. Die Ergebnisse der BDNF-Immunhistologie waren in Hinblick auf die Spezifität zweifelhaft. Schlussfolgerung: Die Nkx 2.1 Daten lassen auf eine ungestörte Migration striataler IN bei der dtsz Mutante schließen. Wahrscheinlich ist eine Ausreifungsstörung für den Mangel an GABAer-gen IN verantwortlich. Die Ergebnisse von KCC2 und CAH7 zeigen, dass keine generelle Ausreifungsstörung von GABAergen Neuronen vorliegt, wobei dies für kleinere Subpopulationen nicht ausgeschlossen werden kann. Entgegen der Arbeitshypothese konnte keine Verringerung sondern eine leichte Erhöhung von BDNF zum 33. LT bei der dtsz Hamstermutante festgestellt werden. Eine mögliche Erklärung könnte sein, dass BDNF auf Grund der verzögert einsetzenden Entwicklung der IN nicht herunterreguliert wird. Die Gründe für diese Erhöhung wie auch weitere Marker für die neuronale Ausreifung werden durch weiterführende Studien untersucht.

Mes travaux de thèse concernent le rôle du récepteur D1 de la dopamine dans les dyskinésies L-dopa induites, effets secondaires extrêmement handicapants du traitement de la maladie de Parkinson. En condition de dénervation striatale mimant l’environnement de la maladie de Parkinson, le traitement chronique par la L-dopa entraine des altérations majeures du trafic intraneuronal et de la signalisation du récepteur D1 de la dopamine dans les principaux neurones cibles de la dopamine, les neurones épineux de taille moyenne du striatum. Il existe en particulier une hypersensibilisation des récepteurs D1 dans les neurones striataux, avec une abondance accrue à la membrane plasmique et une diminution du niveau d’expression de la protéine GRK6 (Protéine kinase des Récepteurs Couplés aux Protéines G 6), un des acteurs clefs des phénomènes de désensibilisation, en relation directe avec l’apparition des dyskinésies.C’est dans ce contexte que se situe mon travail de thèse qui a eu pour objectif de mettre à profit et/ou de développer différents modèles expérimentaux et outils « in vivo » et « in vitro ». Nous avons associé des techniques d’imagerie cellulaire et tissulaire à des approches comportementales, afin d’explorer certains des événements cellulaires et moléculaires à l’échelle du neurone striatal et des réseaux neuronaux, reliant le niveau d’expression du récepteur D1, sa compartimentation cellulaire, son trafic intraneuronal et les dyskinésies ou des conditions pharmacologiques équivalentes.Nous avons confirmé dans le modèle du rat lésé unilatéralement à la 6-OHDA, traité par la L-dopa et développant des mouvements anormaux analogues aux dyskinésies chez l’homme, que le récepteur D1 est anormalement abondant à la membrane plasmique des neurones du striatum, alors qu’il devrait être internalisé après stimulation par son ligand naturel, la dopamine. Nous avons mis en évidence que les mécanismes d’internalisation après stimulation par un agoniste restent néanmoins fonctionnels. Après administration de l’agoniste D1, chez les animaux dyskinétiques, l’abondance des récepteurs D1 augmente dans les compartiments notamment impliqués dans les mécanismes d’internalisation et de transport (vésicules) et de dégradation (corps multivésiculaires). Nous avons apporté une explication possible à cette abondance anormale et à ce défaut d’internalisation, en montrant qu’ils pourraient être dus à une hétérodimérisation entre les récepteurs D1 et D3. La co-activation des récepteurs D1 et D3 par la L-dopa favoriserait l’ancrage du récepteur D1 à la membrane plasmique des neurones striataux.Dans ce cadre, l’abord de l’étude de l’implication du protéasome dans la régulation de l’expression du récepteur D1 de la dopamine nous a semblé particulièrement important, sur la base des premières études soulignant l’implication de ce système catalytique dans le contrôle de l’activité et du métabolisme des récepteurs aux neurotransmetteurs. Nous avons révélé pour la première fois des liens entre l’activité catalytique du protéasome et la dynamique intraneuronale du récepteur D1 et plus particulièrement nous avons montré que son activité chymotrypsine-like est réduite de façon spécifique dans le striatum d’animaux dyskinétiques, comme une conséquence directe d’une déplétion en dopamine associée à une hyperstimulation dopaminergique.Nous avons testé en situation expérimentale une stratégie « thérapeutique » nouvelle en restaurant le mécanisme de désensibilisation homologue du récepteur D1 de la dopamine, par correction du déficit de la kinase GRK6 par transfert du gène correspondant via l’injection intrastriatale d’un vecteur lentiviral. Nous avons montré que cette approche permet de réduire considérablement la sévérité des dyskinésies dans les modèles rat et primate non-humain, analogues des dyskinésies chez l’homme et qu’elle restaure les effets thérapeutiques de la L-dopa. Ces effets sont la conséquence de la restauration des mécanismes de désensibilisation homologue : la surexpression de GRK6 entraîne l’internalisation spécifique des récepteurs D1. L’ensemble de nos résultats s’inscrit dans une démarche de recherche translationnelle menée depuis plusieurs années au laboratoire allant de la cellule au patient, avec pour but de transposer la compréhension des données expérimentales concernant les anomalies de l’expression du récepteur D1 de la dopamine en stratégies thérapeutiques dans les dyskinésies L-dopa induites. Nos investigations montrent qu’il est possible d’agir sur l’expression du récepteur D1 à la membrane plasmique des neurones striataux de manière indirecte, en manipulant trois co-activateurs de son métabolisme, pour espérer réduire « in fine » la sévérité des dyskinésies. / In my thesis work, I studied the role of dopamine D1 receptor in L-dopa induced dyskinesia, a debilitating complication of Parkinson's disease’s treatment. In condition of striatal denervation, that mimics the Parkinson's disease environment, chronic treatment with L-dopa leads to major alterations of intraneuronal trafficking and dopamine D1 receptor signaling in the major target of dopamine neurons, the striatal medium spiny neurons. In particularly, there is a D1 receptor hypersensitivity in striatal neurons, with an increased abundance of D1 receptor at the plasma membrane and a decreased level of GRK6 protein expression, a key actor in desensitization mechanism, directly related with the apparition of dyskinesia.In this context, I used different in vitro and in vivo experimental models and tools. I have associated cell and tissue imaging techniques and behavioural approaches in order to explore cellular and molecular events in striatal neuron and neuronal networks, linking the D1 receptor expression level, its cellular compartmentalization, its intraneuronal trafficking and the dyskinesia behaviour or equivalent pharmacological conditions.We confirmed in the rat analog of L-dopa-induced dyskinesia, i.e., the L-dopa-induced abnormal involuntary movements in unilaterally 6-hydroxydopamine (6-OHDA)-lesioned animals, that D1 receptor is abnormally abundant in the plasma membrane of neurons in the striatum, whereas it should be internalized after stimulation by its natural ligand, the dopamine. We showed that nevertheless the internalization mechanisms after agonist stimulation remains functional. After D1 agonist administration in dyskinetic animals, D1 receptor abundance increases in the cytoplasmic compartments involved in the internalization and transport (vesicles) and degradation (multivesicular bodies) mechanisms. Based on D3 receptor antagonist experiment, we propose that this abnormal abundance and this lack of internalization could be due to heterodimerization between the D1 and D3 receptors. D1 and D3 receptors co-activation by L-dopa might anchor D1 receptor at the plasma membrane of striatal neurons.In this context, analysis of proteasome involvement in the regulation of dopamine D1 receptor expression seemed particularly important, on the basis of the first studies underlying proteasome involvement in the activity and metabolism of neurotransmitter receptors. We demonstrated for the first time links between the proteasomal catalytic activity and D1 receptor intraneuronal dynamics and more particularly we showed that the proteasome chymotrypsin-like activity is reduced specifically in the striatum of dyskinetic animals, as a direct consequence of dopamine depletion associated with dopaminergic hyperstimulation.We tested in experimental condition, a new "therapeutic"strategy in order to restore the dopamine D1 receptor homologous desensitization mechanism, correcting the GRK6 kinase deficit by gene transfer through the intrastriatal injection of a lentiviral vector. We showed that this approach reduces significantly the dyskinesia severity in rat and non-human primate models and restores the L-dopa therapeutic effects. These effects are a consequence of the homologous desensitization mechanisms restoration : indeed GRK6 overexpression provokes specific D1 receptor internalization.Our results are part of a translational research conducted over several years in the laboratory from cell to patient, in order to translate our increased understanding of D1 receptor function abnormalities into therapeutic strategies for L-dopa induced dyskinesia. Our investigations show that it is possible to act on D1 receptor expression at the plasma membrane of striatal neurons via various routes, all resulting into diminished dyskinesia severity.

La peur est ce qui permet de réagir à un stimulus aversif par une réponse de défense adaptée à la situation. Elle peut être générée par un ensemble de stimuli naturellement aversifs ou par des stimuli ayant acquis une valeur aversive par apprentissage associatif. Cette thèse a pour but d'étudier les caractéristiques et modifications de la réponse de peur à ces deux types de stimuli au cours de l'ontogenèse. Les études présentées ici utilisent un conditionnement de peur à l'odeur chez le rat qui associe une odeur à un stimulus aversif et permet d'induire très rapidement et durablement des mémoires de peur à l'odeur. La réponse de défense peut alors être étudiée à la fois envers l'odeur apprise et envers le stimulus naturellement aversif. Nous montrons en particulier que la réponse de peur à l'odeur apprise présente un décours temporel corrélé à la durée de l'intervalle de temps entre l'odeur et le stimulus aversif, permettant d'affirmer que les animaux mémorisent et estiment le temps, et ce dès les premiers âges étudiés, avant la maturation des structures cérébrales classiquement impliquées dans cette mémoire temporelle. Par ailleurs, nous nous sommes intéressés aux vocalisations ultrasonores émises en réponse au stimulus aversif et à leur modification au cours de l'ontogenèse. Nous avons mis en évidence deux types de vocalisations chez le raton, dont les caractéristiques et critères d'induction laissent présager un rôle différentiel qui reste à explorer. L'ensemble de ces travaux soulignent que, même si les réponses de défense du rat changent au cours du développement, la capacité à produire ces réponses de manière temporellement adaptée est observée dès le plus jeune âge / Fear allows individuals to react to an aversive stimulus by a defense response adapted to the situation. It can be triggered by naturally aversive stimuli or in response to stimuli that acquired an aversive valence through associative learning. This thesis investigated the characteristics and modifications of fear responses to these two types of stimuli throughout ontogeny. The studies presented here used olfactory fear conditioning in rat, in which an odor is paired with an aversive event and allows to rapidly induce long lasting odor fear memories. Defense responses can then be studied both to the learned odor and to the naturally aversive stimulus. We showed in particular that fear response to the learned odor presents a temporal pattern correlated with the duration of the time interval between the odor and the aversive event, showing that rats can learn about time and they do so at the youngest ages studied here, before the maturation of the brain structures classically involved in interval timing. We also studied the ultrasonic vocalizations emitted in response to the aversive stimulus and their changes throughout ontogeny. We described two types of vocalizations in pups that differ in their characteristics and emission context, suggesting they could have different functions, which needs further exploration. These thesis findings highlight that although the rat’s defense responses changes through ontogeny, the ability to produce temporally adapted responses occurs from the youngest age

No description available.